Top entities: Evotec, Goldman Sachs, JPMorgan Chase.

What category does this event fall under?

Regulatory — classified as voting rights disclosure.

What is the sentiment of coverage?

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Goldman Sachs changed voting rights Evotec · JPMorgan Chase changed voting rights Evotec

Is this event still developing?

This is an active story, last updated Aug 14, 2026. Coverage continues to evolve.

Regulatory voting rights disclosure

Goldman and JPMorgan disclose Evotec stakes

Q: When did this event occur?

First reported Jun 30, 2026; last updated Aug 14, 2026.

Q: What is the market impact?

General. The disclosures are routine regulatory filings and are unlikely to have a significant impact on Evotec's stock price or the broader market.

Analysis based on 20 articles · First reported Jun 30, 2026 · Last updated Aug 14, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The disclosures are routine regulatory filings and are unlikely to have a significant impact on Evotec's stock price or the broader market. The changes in holdings by major financial institutions may be viewed as neutral, reflecting normal portfolio adjustments and derivative positions.

Pharmaceuticals Financial Services

Event Summary

Evotec, a Hamburg-based drug discovery and development company, has been the subject of multiple voting rights notifications under the German Securities Trading Act (WpHG). Goldman Sachs, Inc. and JPMorgan Chase & Co. have disclosed changes in their holdings of Evotec shares and instruments. Goldman Sachs reported a total position of 14.62% as of June 23, 2026, which later adjusted to 13.70% as of August 7, 2026. JPMorgan Chase reported a total position of 5.18% as of July 10, 2026, and 5.09% as of July 23, 2026. These notifications reflect changes in voting rights attached to shares and financial instruments such as swaps, options, and convertible bonds. The disclosures are routine regulatory filings and do not indicate any specific corporate action or strategic move by the banks.

Key Actions

90 Goldman Sachs changed voting rights Evotec

80 JPMorgan Chase changed voting rights Evotec

Entities Involved

stock

Evotec

Evotec is the issuer subject to the voting rights notifications. The disclosures reflect changes in its shareholder structure but do not indicate any operational or strategic changes.

Importance 100.0 Sentiment 0.0

stock

Goldman Sachs

Goldman Sachs disclosed changes in its voting rights in Evotec, with total positions fluctuating between 13.70% and 14.62%. These changes are part of its normal investment and trading activities.

Importance 80.0 Sentiment 0.0

stock

JPMorgan Chase

JPMorgan Chase disclosed changes in its voting rights in Evotec, with total positions around 5.09% to 5.18%. These changes reflect its portfolio management and derivative positions.

Importance 80.0 Sentiment 0.0

Relationships

Goldman Sachs competitor, counterparty ↔ JPMorgan Chase Goldman Sachs and JPMorgan Chase are direct competitors in investment banking and financial services, frequently vying f

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard